Is Novavax, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Novavax, Inc. moved from expensive to fair. Based on the current metrics, the company appears to be undervalued. The P/E ratio stands at 2, significantly lower than the industry average, while the EV to EBITDA ratio is 1.38 and the PEG ratio is an exceptionally low 0.01, indicating potential for growth relative to its price.
In comparison with peers, Novavax's P/E ratio of 2.87 is notably lower than ADMA Biologics, Inc., which has a P/E of 18.56, highlighting a stark valuation discrepancy. Additionally, Novavax's EV to EBITDA ratio of 1.99 is also much lower than the industry average, reinforcing its undervaluation. Although return data is not available for a direct comparison with the S&P 500, the company's current valuation metrics suggest that it is positioned favorably in the market.